Dr. Thomas M. Taylor, MD
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- Indiana University School of Medicine (1978)
- Years since graduation
- 48
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 407
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1978Medical school: Indiana University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
FL license ME0064670 -
Specialist
FL license ME0064670
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Karon R Locicero MD PA (18 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 407
- Services billed
- 2,715
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 873 | 111 |
| Established patient office or other outpatient visit, 20-29 minutes | 718 | 320 |
| Destruction of precancer skin growth, 1 growth | 240 | 154 |
| Destruction of precancer skin growth, 15 or more growths | 110 | 68 |
| Destruction of skin growth, 1-14 growths | 102 | 78 |
| Biopsy of related skin growth, first growth | 92 | 73 |
| Established patient office or other outpatient visit, 30-39 minutes | 78 | 51 |
| New patient office or other outpatient visit, 30-44 minutes | 52 | 52 |
| New patient office or other outpatient visit, 15-29 minutes | 32 | 32 |
| Established patient office or other outpatient visit, 10-19 minutes | 25 | 23 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Clobetasol Propionate Other prescribers in Tampa, FL | 46 |
| Triamcinolone Acetonide Other prescribers in Tampa, FL | 43 |
| Doxycycline Hyclate Other prescribers in Tampa, FL | 32 |
| Mupirocin Other prescribers in Tampa, FL | 23 |
| Ketoconazole Other prescribers in Tampa, FL | 15 |
| Desonide | 14 |
| Tacrolimus Other prescribers in Tampa, FL | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 78 payments worth $1,952 in total to this clinician.
| Arcutis Biotherapeutics, Inc. | $375 |
|---|---|
| AbbVie Inc. | $287 |
| Sun Pharmaceutical Industries Inc. | $258 |
| Galderma Laboratories, L.P. | $237 |
| Incyte Corporation | $214 |
| E.r. Squibb & Sons, L.l.c. | $214 |
| Botanix Sb Inc | $158 |
| Janssen Biotech, Inc. | $121 |
| Food and Beverage | $1,952 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 5 companies. The companies reported $8,506,155 in research payments for these studies, mostly to the institutions running them.
- A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants
Amgen Inc. - Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
Eli Lilly and Company · Completed · NCT06588283 - A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
Incyte Corporation - A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
Sanofi US Services Inc. · Completed · NCT06224348 - A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
Sanofi US Services Inc. · Active, not recruiting · NCT06241118 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
AbbVie Inc. · Recruiting · NCT06012240 - M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA)
AbbVie Inc. - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
AbbVie Inc. · Active, not recruiting · NCT05889182 - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgrens Syndrome With Moderate-to-Severe Systemic Disease Activity
Amgen Inc. - M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (St…
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.